Mirtazapine Viatris (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases norepinephrine release, and by antagonising serotonin 5‑HT2 and 5‑HT3 receptors while stimulating 5‑HT1A receptors. This dual action enhances both noradrenergic and serotonergic signaling, contributing to its antidepressant effect.

The dosage of Mirtazapine Viatris is individualized by the prescribing clinician based on the patient’s clinical condition, response, and tolerability. The prescriber determines the starting dose and any subsequent adjustments, following local prescribing guidelines.

Safety data for mirtazapine during pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should discuss risks and alternatives with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirtazapine belongs to the NaSSA class, differing from SSRIs and SNRIs by its combined α2‑adrenergic antagonism and serotonergic receptor profile. It often produces sedation and weight gain, which can be advantageous for patients with insomnia or appetite loss, whereas SSRIs are generally more activating and have a different side‑effect spectrum.

Store the tablets at ambient temperature below 25 °C, in the original container, protected from moisture and direct sunlight. Keep out of reach of children and do not use after the expiry date printed on the packaging.

Mirtazapine Viatris is taken orally, usually once daily in the evening. Tablets should be swallowed whole with water and not chewed or crushed, unless otherwise directed by a healthcare professional.

Serious risks include the emergence of suicidal thoughts, especially early in treatment, agranulocytosis (a severe drop in white blood cells), and serotonin syndrome when combined with other serotonergic drugs. Patients should be monitored closely for any signs of these conditions.

Mirtazapine should be avoided in patients with known hypersensitivity to the drug, those who have taken a monoamine oxidase inhibitor within the past 14 days, and individuals with severe hepatic impairment unless a specialist advises otherwise.